3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab

Size: px
Start display at page:

Download "3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab"

Transcription

1 Search strategy for MEDLINE Steatosis: 1. fatty liver/ 2. non-alcoholic fatty liver disease/ 3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab 4. (nafl* or nash).ti,ab. 5. or/ letter/ 7. editorial/ 8. news/ 9. exp historical article/ 10. anecdotes as topic/ 11. comment/ 12. case report/ 13. (letter or comment*).ti. 14. or/ randomized controlled trial/ or random*.ti,ab not animals/ not humans/ 18. exp animals, laboratory/ 19. exp animal experimentation/ 20. exp models, animal/ 21. exp rodentia/ 22. (rat or rats or mouse or mice).ti. 23. or/ not

2 26. limit 24 to English language 27. alanine transaminase/ 28. aspartate aminotransferases/ 29. gamma-glutamyltransferase/ 30. (test* or measure* or level* or ratio*).ti,ab. 31. or/ and ((alanine transaminase* or alt or aspartate aminotransferase* or ast or gamma glutamyltransferase* or gamma gt or gammagt or ggt) adj4 (test* or measure* or level* or ratio*)).ti,ab. 34. (fatty liver ind* or fli).ti,ab. 35. (steatotest or steato test).ti,ab. 36. liver fat scor*.ti,ab. 37. ultrasonography/ or exp ultrasonography, doppler/ 38. (ultrasound* or ultrason* or sonograph* or echograph*).ti,ab. 39. magnetic resonance imaging/ 40. magnetic resonance spectroscopy/ 41. (mri or mrs or ((magnetic or mr) adj2 (imag* or spectroscop*))).ti,ab. 42. controlled attenuation parameter.ti,ab. 43. elasticity imaging techniques/ 44. alanine transaminase/ 45. or/ and exp "sensitivity and specificity"/ 48. (sensitivity or specificity).ti,ab. 49. ((pre test or pretest or post test) adj probability).ti,ab. 50. (predictive value* or ppv or npv).ti,ab. 51. likelihood ratio*.ti,ab.

3 52. likelihood function/ 53. (roc curve* or auc).ti,ab. 54. (diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. 55. gold standard.ab. 56. or/ and limit 57 to yr="2015 -Current" Fibrosis: 1. fatty liver/ 2. non-alcoholic fatty liver disease/ 3. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab. 4. (nafl* or nash).ti,ab. 5. or/ letter/ 7. editorial/ 8. news/ 9. exp historical article/ 10. anecdotes as topic/ 11. comment/ 12. case report/ 13. (letter or comment*).ti. 14. or/ randomized controlled trial/ or random*.ti,ab not animals/ not humans/ 18. exp animals, laboratory/ 19. exp animal experimentation/

4 20. exp models, animal/ 21. exp rodentia/ 22. (rat or rats or mouse or mice).ti. 23. or/ not limit 24 to english language 26. biological markers/ 27. alanine transaminase/ 28. exp aspartate aminotransferases/ 29. keratin-18/ 30. ferritin/ 31. or/ (test* or measure* or level* or diagnos* or ratio or score*).ti,ab and (fibro test* or fibro-test* or fibrometer or fibroscan or fib4 or fib-4).ti,ab. 35. ((nafld or bard or ferritin* or fibrosis) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 36. ((glutamic-pyruvic transaminase or glutamic-oxaloacetic transaminase or sgot or sgpt or alt or ast) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 37. (aspartate adj2 (aminotransferase or apoaminotransferase or transaminase) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 38. (alanine adj2 (aminotransferase or transaminase) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 39. ((ast-to-platelet ratio index or apri or elf or enhanced liver fibrosis or nash) adj4 (test* or measure* or level* or score*)).ti,ab. 40. ((biomarker* or marker*) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 41. exp magnetic resonance spectroscopy/ 42. exp diffusion magnetic resonance imaging/ 43. (elastogra* or sonoelastogra* or elasticity imag* or sheer wave).ti,ab. 44. (acoustic radiation force impulse or arfi).ti,ab.

5 45. ((diffusion or weighted) adj2 (imag* or mri)).ti,ab. 46. (mrs or ((nmr or magnetic or mr) adj2 spectroscop*)).ti,ab. 47. or/ and exp "sensitivity and specificity"/ 50. (sensitivity or specificity).ti,ab. 51. ((pre test or pretest or post test) adj probability).ti,ab. 52. (predictive value* or ppv or npv).ti,ab. 53. likelihood ratio*.ti,ab. 54. likelihood function/ 55. (roc curve* or auc).ti,ab. 56. (diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. 57. gold standard.ab. 58. or/ and limit 59 to yr="2015 -Current" Search strategy for EMBASE Steatosis 1. nonalcoholic fatty liver/ 2. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab. 3. (nafl* or nash).ti,ab. 4. or/ letter.pt. or letter/ 6. note.pt. 7. editorial.pt. 8. case report/ or case study/ 9. (letter or comment*).ti.

6 10. conference*.pt. 11. or/ randomized controlled trial/ or random*.ti,ab not animal/ not human/ 15. nonhuman/ 16. exp animal experiment/ 17. exp experimental animal/ 18. animal model/ 19. exp rodent/ 20. (rat or rats or mouse or mice).ti. 21. or/ not limit 22 to english language 25. *alanine aminotransferase/ 26. *aspartate aminotransferase/ 27. *gamma glutamyltransferase/ 28. or/ (test* or measure* or level* or ratio*).ti,ab and ((alanine transaminase* or alt or aspartate aminotransferase* or ast or gamma glutamyltransferase* or gamma gt or gammagt or ggt) adj4 (test* or measure* or level* or ratio*)).ti,ab. 32. (fatty liver ind* or fli).ti,ab. 33. (steatotest or steato test).ti,ab. 34. liver fat scor*.ti,ab. 35. *echography/ or *doppler echography/

7 36. (ultrasound* or ultrason* or sonograph* or echograph*).ti,ab. 37. *nuclear magnetic resonance imaging/ 38. *nuclear magnetic resonance spectroscopy/ 39. (mri or mrs or ((magnetic or mr) adj2 (imag* or spectroscop*))).ti,ab. 40. controlled attenuation parameter.ti,ab. 41. *elastography/ 42. or/ and exp "sensitivity and specificity"/ 45. (sensitivity or specificity).ti,ab. 46. ((pre test or pretest or post test) adj probability).ti,ab. 47. (predictive value* or ppv or npv).ti,ab. 48. likelihood ratio*.ti,ab. 49. likelihood function/ 50. (roc curve* or auc).ti,ab. 51. (diagnos* adj3 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. 52. gold standard.ab. 53. or/ and limit 54 to yr="2015 -Current" Fibrosis: 1. nonalcoholic fatty liver/ 2. (((fatty or fat or steato*) adj3 (liver* or hepat*)) or steatohepat* or (visceral adj2 steato*)).ti,ab. 3. (nafl* or nash).ti,ab. 4. or/ letter.pt. or letter/ 6. note.pt.

8 7. editorial.pt. 8. case report/ or case study/ 9. (letter or comment*).ti. 10. or/ randomized controlled trial/ or random*.ti,ab not animal/ not human/ 14. nonhuman/ 15. exp animal experiment/ 16. exp experimental animal/ 17. animal model/ 18. exp rodent/ 19. (rat or rats or mouse or mice).ti. 20. or/ not limit 21 to english language 23. biological marker/ 24. alanine aminotransferase/ 25. exp aspartate aminotransferases/ 26. cytokeratin 18/ 27. ferritin/ 28. or/ (test* or measure* or level* or diagnos* or ratio or score*).ti,ab and (fibro test* or fibro-test* or fibrometer or fibroscan or fib4 or fib-4).ti,ab. 32. ((nafld or bard or ferritin* or fibrosis) adj4 (test* or measure* or level* or ratio or score*)).ti,ab.

9 33. ((glutamic-pyruvic transaminase or glutamic-oxaloacetic transaminase or sgot or sgpt or alt or ast) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 34. (aspartate adj2 (aminotransferase or apoaminotransferase or transaminase) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 35. (alanine adj2 (aminotransferase or transaminase) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 36. ((ast-to-platelet ratio index or apri or elf or enhanced liver fibrosis or nash) adj4 (test* or measure* or level* or score*)).ti,ab. 37. ((biomarker* or marker*) adj4 (test* or measure* or level* or ratio or score*)).ti,ab. 38. exp nuclear magnetic resonance spectroscopy/ 39. exp diffusion weighted imaging/ 40. (elastogra* or sonoelastogra* or elasticity imag* or sheer wave).ti,ab. 41. (acoustic radiation force impulse or arfi).ti,ab. 42. ((diffusion or weighted) adj2 (imag* or mri)).ti,ab. 43. (mrs or ((nmr or magnetic or mr) adj2 spectroscop*)).ti,ab. 44. or/ and exp "sensitivity and specificity"/ 47. (sensitivity or specificity).ti,ab. 48. ((pre test or pretest or post test) adj probability).ti,ab. 49. (predictive value* or ppv or npv).ti,ab. 50. likelihood ratio*.ti,ab. 51. (roc curve* or auc).ti,ab. 52. (diagnos* adj2 (performance* or accurac* or utilit* or value* or efficien* or effectiveness)).ti,ab. 53. diagnostic accuracy/ 54. diagnostic test accuracy study/ 55. gold standard.ab. 56. or/ and 56

10 58. limit 57 to yr="2015 -Current" Search strategy for Cochrane library collection Steatosis: #1 [mh ^"fatty liver"] #2 MeSH descriptor: [Non-alcoholic Fatty Liver Disease] this term only #3 (((fatty or fat or steato*) near/3 (liver* or hepat*)) or steatohepat* or (visceral near/2 steato*)):ti,ab #4 (nafl* or nash):ti,ab #5 {or #1-#4} #6 [mh ^"alanine transaminase"] #7 [mh ^"aspartate aminotransferases"] #8 [mh ^gamma-glutamyltransferase] #9 {or #2-#4} #10 (test* or measure* or level* or ratio*):ti,ab #11 #5 and #6 #12 ((alanine next transaminase* or alt or aspartate next aminotransferase* or ast or gamma next glutamyltransferase* or gamma next gt or gammagt or ggt) near/4 (test* or measure* or level* or ratio*)):ti,ab #13 (fatty next liver next ind* or fli):ti,ab #14 (steatotest or steato next test):ti,ab #15 liver next fat next scor*:ti,ab #16 [mh ^ultrasonography] #17 [mh "ultrasonography, doppler"] #18 (ultrasound* or ultrason* or sonograph* or echograph):ti,ab #19 [mh ^"magnetic resonance imaging"] #20 [mh ^"magnetic resonance spectroscopy"] #21 (mri or mrs or ((magnetic or mr) near/2 (imag* or spectroscop*))):ti,ab #22 controlled attenuation parameter:ti,ab #23 [mh ^"elasticity imaging techniques"]

11 #24 {or #11-#23} #25 #4 and #24 Publication Year from 2015 to 2017 Fibrosis #1 [mh ^"fatty liver"] #2 MeSH descriptor: [Non-alcoholic Fatty Liver Disease] this term only #3 (((fatty or fat or steato*) near/3 (liver* or hepat*)) or steatohepat* or (visceral near/2 steato*)):ti,ab #4 (nafl* or nash):ti,ab #5 {or #1-#4} #6 MeSH descriptor: [Biomarkers] this term only #7 MeSH descriptor: [Alanine Transaminase] explode all trees #8 MeSH descriptor: [Keratin-18] this term only #9 MeSH descriptor: [Ferritins] this term only #10 {or #2-#6} #11 (test* or measure* or level* or ratio or diagnos* or score*):ti,ab #12 #7 and #8 #13 (fibro test* or fibro-test* or fibrometer or fibroscan or fib4 or fib-4):ti,ab #14 ((nafld or bard or ferritin* or fibrosis) near/4 (test* measure* or level* or ratio or score*)):ti,ab #15 ((glutamic-pyruvic transaminase or glutamic-oxaloacetic transaminase or sgot or sgpt or alt or ast) near/4 (test* or measure* or level* or ratio or score*)):ti,ab #16 (aspartate near/2 (aminotransferase or apoaminotransferase or transaminase) near/4 (test* or measure* or level* or ratio or score*)):ti,ab #17 (alanine near/2 (aminotransferase or transaminase) near/4 (test* or measure* or level* or ratio or score*)):ti,ab #18 ((ast-to-platelet raio index or apri or elf or enhanced liver fibrosis or nash) near/4 (test* or measure* or level* or score*)):ti,ab #19 ((biomarker* or marker*) near/4 (test* or measure* or level* or ratio or score*)):ti,ab #20 MeSH descriptor: [Magnetic Resonance Spectroscopy] explode all trees #21 MeSH descriptor: [Diffusion Magnetic Resonance Imaging] explode all trees

12 #22 (elastogra* or sonoelastogra* or elasticity imag* or sheer wave):ti,ab #23 (acoustic radiation force impulse or arfi):ti,ab #24 ((diffusion or weighted) near/2 (imag* or mri)):ti,ab #25 (mrs or ((nmr or magneetic or mr) near/2 spectroscop*)):ti,ab #26 {or #12-#25} #27 #10 and #26 #28 #5 and #27 Publication Year from 2015 to 2017 Science Index Expanded Steatosis 1 (TS=(fatty liver OR nonalcoholic fatty liver OR non-alcoholic fatty liver disease*)) AND LANGUAGE: (English) 2 (TS=((fatty OR fat or steato*)near(liver* or hepat*))) AND LANGUAGE: (English) 3 (TS=(steatohepat* OR (visceral NEAR steato*))) AND LANGUAGE: (English) 4 (TS=("NAFLD" OR NAFL* OR NASH)) AND LANGUAGE: (English) 5 (#4 OR #3 OR #2 OR #1) AND LANGUAGE: (English) 6 (DT=(conference* OR letter* OR editorial* OR news* or historical* OR comment* OR case*)) AND LANGUAGE: (English) 7 (TS=(RCT OR randomi$ed controlled trial)) AND LANGUAGE: (English) 8 (#6 NOT #7) AND LANGUAGE: (English) 9 (TS=(animal* or animal model* or animal experimentation OR rodentia OR animals laboratory)) AND LANGUAGE: (English) 10 (TI=(rat* or mouse or mice)) AND LANGUAGE: (English) 11 (TS=(animal* NOT human*)) AND LANGUAGE: (English) 12 #11 OR #10 OR #9 13 (#5 NOT #12) AND LANGUAGE: (English) 14 (TS=(alanine transaminase* OR ALT)) AND LANGUAGE: (English) 15 (TS=(aspartate aminotransferase* OR AST)) AND LANGUAGE: (English) 16 (TS=(gamma-glutamyltransferase* or gamma glutamyltransferase* or GGT)) AND LANGUAGE: (English)

13 17 (TS=(test* or measure* or level* or ratio*)) AND LANGUAGE: (English) 18 #16 OR #15 OR #14 19 #18 AND #17 20 (TS=(fatty liver ind* OR "fatty liver index" OR fli)) AND LANGUAGE: (English) 21 (TS=(steatotest OR steato test)) AND LANGUAGE: (English) 22 (TS=(liver fat scor*)) AND LANGUAGE: (English) 23 (TS=(ultrasonograph* OR ultrasound* OR sonograph* or echograph*)) AND LANGUAGE: (English) 24 (TS=(magnetic resonance imaging* OR magnetic resonance spectroscop* OR MRI OR MRS)) AND LANGUAGE: (English) 25 (TS=((controlled attenuation parameter NEAR "CAP") OR elasticity imaging technique*)) AND LANGUAGE: (English) 26 (#25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19) AND LANGUAGE: (English) 27 #26 AND #13 28 (TS=( sensitivity and specificity)) AND LANGUAGE: (English) 29 (TS=(predictive value* or ppv or npv or likelihood ra tio* or roc curve* or auc)) AND LANGUAGE: (English) 30 (TS=(diagnostic accuracy OR diagnostic test accuracy study)) AND LANGUAGE: (English) 31 (TS=(diagnos* NEAR (performance* OR accurac* or utilit* or value* or efficien* or effectiveness))) AND LANGUAGE: (English) 32 (TS=(biops* AND gold standard)) AND LANGUAGE: (English) 33 #32 OR #31 OR #30 OR #29 OR #28 34 #33 AND #27 Indexes=SCI-EXPANDED Timespan= Fibrosis 1 (TS=(fatty liver OR nonalcoholic fatty liver OR non-alcoholic fatty liver disease*)) AND LANGUAGE: (English) 2 (TS=((fatty OR fat or steato*)near(liver* or hepat*))) AND LANGUAGE: (English) 3 (TS=(steatohepat* OR (visceral NEAR steato*))) AND LANGUAGE: (English) 4 (TS=("NAFLD" OR NAFL* OR NASH)) AND LANGUAGE: (English) 5 (#4 OR #3 OR #2 OR #1) AND LANGUAGE: (English)

14 6 (DT=(conference* OR letter* OR editorial* OR news* or historical* OR comment* OR case*)) AND LANGUAGE: (English) 7 (TS=(RCT OR randomi$ed controlled trial)) AND LANGUAGE: (English) 8 (#6 NOT #7) AND LANGUAGE: (English) 9 (TS=(animal* or animal model* or animal experimentation OR rodentia OR animals laboratory)) AND LANGUAGE: (English) 10 (TI=(rat* or mouse or mice)) AND LANGUAGE: (English) 11 (TS=(animal* NOT human*)) AND LANGUAGE: (English) 12 #11 OR #10 OR #9 13 (#5 NOT #12) AND LANGUAGE: (English) 14 (TS=(alanine transaminase* OR ALT)) AND LANGUAGE: (English) 15 (TS=(aspartate aminotransferase* OR AST)) AND LANGUAGE: (English) 16 TS=(gamma-glutamyltransferase* or gamma glutamyltransferase* or GGT or keratin?18 or ferritin or biological marker* or biomarker*) 17 TS=(test* or measure* or level* or ratio* or diagnos*) 18 #16 OR #15 OR #14 19 #18 AND #17 20 TS=((fibro test* or fibro-test* or fibrometer or fibroscan or fib4 or fib-4 or glutamic-pyruvic transaminase or glutamic-oxaloacetic transaminase or sgot or sgpt or nafld or bard or ferritin* or fibrosis or ast-to-platelet ratio OR apri or elf or "enhanced liver fibrosis" or nash or biomarker* or marker*) AND (test* or measure* or level* or ratio or score* or index)) 21 TS=((aspartate OR alanine) AND (aminotransferase OR apoaminotransferase or transaminase) AND (test* or level* or measure* or ratio or score*)) 22 TS=(magnetic resonance spectroscop* OR MRS OR "magnetic resonance imaging" OR MRI) 23 TS=(ultrasonograph* OR ultrasound* OR sonograph* or echograph* OR sonoelastogra* or elasticity imag* or "sheer wave" or acoustic radiation force impulse OR arfi) 24 TS=((diffusion or weighted) AND (imag* or mri)) 25 TS=(MRS OR (NMR or magnetic or mr)near spectroscop*) 26 (#25 OR #24 OR #23 OR #22 OR #21 OR #20 OR #19) AND LANGUAGE: (English) 27 #26 AND #13 28 (TS=( sensitivity and specificity)) AND LANGUAGE: (English)

15 29 (TS=(predictive value* or ppv or npv or likelihood ra tio* or roc curve* or auc)) AND LANGUAGE: (English) 30 (TS=(diagnostic accuracy OR diagnostic test accuracy study)) AND LANGUAGE: (English) 31 (TS=(diagnos* NEAR (performance* OR accurac* or utilit* or value* or efficien* or effectiveness))) AND LANGUAGE: (English) 32 (TS=(biops* AND gold standard)) AND LANGUAGE: (English) 33 #32 OR #31 OR #30 OR #29 OR #28 34 #33 AND #27 Indexes=SCI-EXPANDED Timespan=

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis

The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis The role of non-invasivemethods in evaluating liver fibrosis of patients with non-alcoholic steatohepatitis Objectives: Liver biopsy is the gold standard for diagnosing the extent of fibrosis in NAFLD/NASH;

More information

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease

In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease REVIEW In Search of New Biomarkers for Nonalcoholic Fatty Liver Disease Ting-Ting Chan, M.R.C.P., and Vincent Wai-Sun Wong, M.D. Nonalcoholic fatty liver disease (NAFLD) affects 15% to 40% of the general

More information

Diagnostic Challenges of Nonalcoholic Fatty Liver Disease/ Nonalcoholic Steatohepatitis

Diagnostic Challenges of Nonalcoholic Fatty Liver Disease/ Nonalcoholic Steatohepatitis REVIEW Diagnostic Challenges of Nonalcoholic Fatty Liver Disease/ Nonalcoholic Steatohepatitis Erin Cleveland, M.D.,* Andrew Bandy, M.D., and Lisa B. VanWagner, M.D., M.Sc. *, Nonalcoholic fatty liver

More information

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2019 Origination: 2/2017 Next Review: 2/2020 Policy Blue Cross and

More information

Cerebral palsy in under 25s: assessment and management

Cerebral palsy in under 25s: assessment and management National Institute for Health and Care Excellence Final Version Cerebral palsy in under 25s: assessment and management Appendix E Search Strategies NICE Guideline NG62 Methods, evidence and recommendations

More information

Appendix F: Literature search strategies

Appendix F: Literature search strategies Appendix F: Contents Introduction Section F.1 F.1.1 F.1.2 F.1.3 F.1.4 F.1.5 F.1.6 Section F.2 Section F.3 F.3.1 F.3.2 F.3.3 F.3.4 F.3.5 F.3.6 Section F.4 F.4.1 F.4.2 Search methodology Study filter terms

More information

Renal and ureteric stones: assessment and management

Renal and ureteric stones: assessment and management National Institute for Health and Care Excellence Consultation Renal and ureteric stones: assessment and management Metabolic investigations NICE guideline Intervention evidence review July 08 Consultation

More information

Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review

Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review Practical Diagnosis and Staging of Nonalcoholic Fatty Liver Disease: A Narrative Review Authors: Jennifer Gallacher, 1 *Stuart McPherson 1,2 1. Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman

More information

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Policy Number: 2.04.41 Last Review: 2/2018 Origination: 2/2017 Next Review: 2/2019 Policy Blue Cross and

More information

MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease

MP Noninvasive Techniques for the Evaluation and Monitoring of Patients With Chronic Liver Disease Medical Policy BCBSA Ref. Policy: 2.04.41 Last Review: 11/15/2018 Effective Date: 11/15/2018 Section: Medicine Related Policies 9.01.502 Experimental / Investigational Services DISCLAIMER Our medical policies

More information

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI

Update on Non-Alcoholic Fatty Liver Disease. Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI Update on Non-Alcoholic Fatty Liver Disease Timothy R. Morgan, MD Chief, Hepatology, VA Long Beach Professor of Medicine, UCI February 3, 2018 Disclosure Clinical trials: Genfit Speaker s Bureau: none

More information

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD

Noninvasive Diagnosis and Staging of Liver Disease. Naveen Gara, MD Noninvasive Diagnosis and Staging of Liver Disease Naveen Gara, MD Outline Brief overview of the anatomy of liver Liver-related lab tests Chronic liver disease progression Estimation of liver fibrosis

More information

Renal and ureteric stones: assessment and management

Renal and ureteric stones: assessment and management National Institute for Health and Care Excellence Final Renal and ureteric stones: assessment and management Metabolic investigations NICE guideline NG118 Intervention evidence review (A) January 2019

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Noninvasive Techniques for the Evaluation and Monitoring of Page 1 of 38 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation

More information

Preoperative tests (update)

Preoperative tests (update) . Preoperative tests (update) Routine preoperative tests for elective surgery NICE guideline NG45 Appendix G: April 2016 Developed by the National Guideline Centre, hosted by the Royal College of Physicians.

More information

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases

The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases RESEARCH ARTICLE The role of ARFI and APRI in diagnosis of liver fibrosis on patients with common chronic liver diseases Objective: This study aimed to investigate the value of liver fibrosis assessment

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Noninvasive Techniques for the Evaluation and Page 1 of 34 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Noninvasive Techniques for the Evaluation and Professional

More information

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014

NASH : Diagnosis and investigation. VII Workshop international, Curitiba, Brazil 29/08/2014 NASH : Diagnosis and investigation VII Workshop international, Curitiba, Brazil 29/08/2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France Usual diagnostic circumstances

More information

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup

Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup REVIEW REVIEW Nonalcoholic Fatty Liver Disease: Definitions, Risk Factors, and Workup Puneet Puri, M.B.B.S., M.D. and Arun J. Sanyal, M.B.B.S., M.D. Nonalcoholic fatty liver disease (NAFLD) is defined

More information

NAFLD and NASH: The Not-So-New Kids on the Block

NAFLD and NASH: The Not-So-New Kids on the Block NAFLD and NASH: The Not-So-New Kids on the Block Mary E. Rinella, MD Associate Professor of Medicine Feinberg School of Medicine Northwestern University Chicago, Illinois This program is supported by an

More information

IS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE?

IS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE? Rev. Med. Chir. Soc. Med. Nat., Iaşi 2016 vol. 120, no. 3 INTERNAL MEDICINE - PEDIATRICS UPDATES IS LIVER BIOPSY NECESSARY IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE? R. S. Gavril 1, Laura Mihalache

More information

Bilag 5. Søgestreng sekundær og primær litteratur

Bilag 5. Søgestreng sekundær og primær litteratur Bilag 5. Søgestreng sekundær og primær litteratur Søgespecialister Conni Skrubbeltrang og Jette Frost Jepsen Det Nationale Sorgcenter Database Udbyder Resultat Dato Medline Ovid 61 26.06.2017 Embase Ovid

More information

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain

NAFLD: evidence-based management. Curso de residentes AEEH Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain NAFLD: evidence-based management Curso de residentes AEEH 2017 Salvador Augustin, MD Liver Unit Vall d Hebron Hospital Barcelona, Spain Clinical case - 55 yo female - Sent for incidental steatosis at abdominal

More information

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis

Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts NAS score for NASH diagnosis Alina M. Allen, Meng Yin, Sudhakar K. Venkatesh, Taofic Mounajjed, Todd A. Kellogg,

More information

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice. Advice Statement 010-18 July 2018 Advice Statement What is the most accurate and cost-effective direct test (ELF test, hyaluronic acid, P3NP, Fibroscan or ARFI elastography) for detecting and staging liver

More information

Non-Invasive Testing for Liver Fibrosis

Non-Invasive Testing for Liver Fibrosis NORTHWEST AIDS EDUCATION AND TRAINING CENTER Non-Invasive Testing for Liver Fibrosis John Scott, MD, MSc Associate Professor, University of Washington Associate Clinic Director, Hep/Liver Clinic, Harborview

More information

Page: 1 of 19. Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease

Page: 1 of 19. Noninvasive Techniques for the Evaluation and Monitoring of Patients with Chronic Liver Disease and Monitoring of Patients with Chronic Liver Page: 1 of 19 Last Review Status/Date: March 2015 and Monitoring of Patients with Chronic Liver Description Options for noninvasive monitoring of liver fibrosis

More information

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning

Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Improved Hepatic Fibrosis Grading Using Point Shear Wave Elastography and Machine Learning Presenter: Hersh Sagreiya 1, M.D. Authors: Alireza Akhbardeh 1, Ph.D., Isabelle Durot 1, M.D., Carlo Filice 2,

More information

Liver Fat Quantification

Liver Fat Quantification Liver Fat Quantification Jie Deng, PhD, DABMP Department of Medical Imaging May 18 th, 2017 Disclosure Research agreement with Siemens Medical Solutions 2 Background Non-alcoholic fatty liver diseases

More information

Supplementary appendix

Supplementary appendix Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Harris R, Harman DJ, Card TR, Aithal GP, Guha

More information

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE

NONINVASIVE TECHNIQUES FOR EVALUATION AND MONITORING OF CHRONIC LIVER DISEASE LIVER DISEASE Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are

More information

Medical Policy Non-invasive Tests for Hepatic Fibrosis

Medical Policy Non-invasive Tests for Hepatic Fibrosis Medical Policy Non-invasive Tests for Hepatic Fibrosis Subject: Non-invasive Tests for Hepatic Fibrosis Background: Accurately diagnosing liver fibrosis and inflammatory activity are the most important

More information

NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH

NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH NONINVASIVE IMAGING METHODS FOR ASSESSMENT OF LIVER DAMAGE IN NASH Bachir Taouli, MD Director of Body MRI and Cancer Imaging Program Department of Radiology / Translational and Molecular Imaging Institute

More information

Monitoring Hepatitis C

Monitoring Hepatitis C Monitoring Hepatitis C Section Six Monitoring Hepatitis C Screening for hepatitis C is not routinely done, so you may have to request a test from your medical provider. This usually involves an antibody

More information

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008 Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Non-alcoholic fatty liver disease

Non-alcoholic fatty liver disease Non-alcoholic fatty liver disease Link to this article online for CPD/CME credits Naveed Sattar, 1 Ewan Forrest, 2 David Preiss 1 1 BHF Glasgow Cardiovascular Research Centre, University of Glasgow, Glasgow

More information

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease

Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease 1 Liver Unit, Newcastle Upon Tyne Hospitals NHS Trust, Freeman Hospital, Newcastle upon Tyne, UK 2 Institute of Cellular Medicine, Faculty of Medical Sciences, Newcastle University, Newcastle Upon Tyne,

More information

The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease

The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease POSITION STATEMENT 1 The Belgian Association for Study of the Liver Guidance Document on the Management of Adult and Paediatric Non-Alcoholic Fatty Liver Disease S. Francque 1,2, N. Lanthier 3, L. Verbeke

More information

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study

Assessment of Liver Stiffness by Transient Elastography in Diabetics with Fatty Liver A Single Center Cross Sectional observational Study IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 6 Ver. IV (June. 2017), PP 49-53 www.iosrjournals.org Assessment of Liver Stiffness by Transient

More information

Literature search strategies

Literature search strategies Literature search strategies A.1.1 Contents Introduction Section A.1.2 Section A.1.3 A.1.3.1 A.1.3.2 A.1.3.3 A.1.3.4 A.1.3.5 A.1.3.6 A.1.3.7 Section A.1.4 A.1.4.1 A.1.4.2 A.1.4.3 A.1.4.4 A.1.4.5 A.1.4.6

More information

Liver elastography ultrasound cpt code

Liver elastography ultrasound cpt code Liver elastography ultrasound cpt code In a multi-center study, Barbero-Villares et al (2012) evaluated the presence of significant liver fibrosis by transient elastography (FibroScan) in inflammatory.

More information

Urinary incontinence and pelvic organ prolapse in women: management

Urinary incontinence and pelvic organ prolapse in women: management National Institute for Health and Care Excellence Final Urinary incontinence and pelvic organ prolapse in women: management [G] Evidence review for assessing pelvic organ prolapse NICE guideline NG123

More information

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob

What is NAFLD?.NASH? Presenter Disclosure Information. Learning Objectives. Case 1: Rob. Questions Pertinent to Rob Presenter Disclosure Information 5 6pm Nonalcoholic Fatty Liver Disease (NAFLD): Another Obesity-Related Epidemic SPEAKER Elliot Tapper, MD The following relationships exist related to this presentation:

More information

Non-invasive diagnostic biomarkers

Non-invasive diagnostic biomarkers Non-invasive diagnostic biomarkers Liver Forum, November 12 th, 2015 Rohit Loomba, MD, MHSc Professor of Medicine (with tenure) Director, NAFLD Research Center, Division of Gastroenterology, Department

More information

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity

Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Preliminary clinical experience with Shear Wave Dispersion Imaging for liver viscosity Dr. Katsutoshi Sugimoto Department of Gastroenterology and Hepatology, Tokyo Medical University, Japan Introduction

More information

In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network

In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network Evidence Note Number 82 July 2018 In response to an enquiry from the Scottish Clinical Biochemistry Managed Diagnostic Network What is the most accurate and cost-effective direct test (ELF test, hyaluronic

More information

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust

ABNORMAL LIVER FUNCTION TESTS. Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust ABNORMAL LIVER FUNCTION TESTS Dr Uthayanan Chelvaratnam Hepatology Consultant North Bristol NHS Trust INTRODUCTION Liver function tests Cases Non invasive fibrosis measurement Questions UK MORTALITY RATE

More information

Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know

Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Non-Alcoholic Steatohepatitis (NASH): What the Gastroenterologist Should Know Naga P. Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Objective At the end of this lecture, the learner will be able to: Outline the appropriate evaluation of a person infected with HCV in order to assess the benefits and risks of

More information

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis

Bio Predictive. FibroTest/FibroSure Scientific Publications. Houot 2015 FibroTest, TE, FIB-4, APRI Meta-analysis AASLD 2015 /FibroSure Scientific Publications Section 1 - compared to APRI, FIB-4 and transient elastography Houot 2015, TE, FIB-4, APRI Meta-analysis is superior to TE by Fibroscan, APRI and Fib-4 using

More information

Abstract. Introduction

Abstract. Introduction Med. J. Cairo Univ., Vol. 82, No. 2, September: 185-194, 2014 www.medicaljournalofcairouniversity.net Performance of Acoustic Radiation Force Impulse Imaging in Staging Liver Fibrosis and Cirrhosis in

More information

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH

When to Treat: Staging Liver Disease David L. Thomas, MD, MPH When to Treat: Staging Liver Disease David L. Thomas, MD, MPH Professor of Medicine Johns Hopkins School of Medicine Disclosures Received royalties from UpToDate, Inc. Staging refers to the assessment

More information

Clinical Policy Title: Liver elastography

Clinical Policy Title: Liver elastography Clinical Policy Title: Liver elastography Clinical Policy Number: CCP.1118 Effective Date: October 1, 2014 Initial Review Date: June 18, 2014 Most Recent Review Date: August 7, 2018 Next Review Date: August

More information

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014 Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead

More information

2 nd International Workshop on NASH Biomarkers, Washington DC, May 5-6, 2017

2 nd International Workshop on NASH Biomarkers, Washington DC, May 5-6, 2017 Hepatic Proton Density Fat Fraction Correlates With Histologic Measures of Steatosis and Is Responsive to Changes in Those Measures in a Multi-center Nonalcoholic Steatohepatitis Clinical Trial Michael

More information

Bio Predictive. FibroTest Scientific Publications. Ratziu 2016 FibroMax NASH. Friedman 2016 FibroTest NASH EASL Key Publications for 2017

Bio Predictive. FibroTest Scientific Publications. Ratziu 2016 FibroMax NASH. Friedman 2016 FibroTest NASH EASL Key Publications for 2017 EASL 2017 Scientific Publications Ratziu 2016 NASH Friedman 2016 NASH SteatoTest and sensitive markers of improvement in NASH trial using Elafibranor Elafibranor, an agonist of the peroxisome proliferator

More information

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease

Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic Fatty Liver Disease Gut and Liver, Vol. 10, No. 2, March 2016, pp. 295-302 ORiginal Article Relationship between Controlled Attenuation Parameter and Hepatic Steatosis as Assessed by Ultrasound in Alcoholic or Nonalcoholic

More information

The classical metabolic work-up, approved by the Ethics Committee of the Antwerp

The classical metabolic work-up, approved by the Ethics Committee of the Antwerp SUPPLEMENTARY MATERIALS METHODS Metabolic work-up The classical metabolic work-up, approved by the Ethics Committee of the Antwerp University Hospital and requiring written informed consent, included a

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO

PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO PROPOSTA DI UN NUOVO ALGORIMO PER LA DIAGNOSI ECOGRAFICA DELLE MALATTIE CRONICHE DEL FEGATO A. Giorgio Direttore del servizio di Ecografia Interventistica Istituto Clinico S.Rita -IRCCS -Atripalda (Avellino)

More information

Section: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013

Section: Laboratory Last Reviewed Date: June Policy No: 47 Effective Date: August 1, 2013 Medical Policy Manual Topic: Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Date of Origin: June 2013 Section: Laboratory Last Reviewed

More information

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT

/ FIB4 Index , simple steatosis. FIB4 Index. FIB4 Index. FIB4 Index FIB4 Index. Sterling FIB4 Index. FIB4 Index AST AST ALT 原 著 29 34-41, 2014 FIB4 Index 1 1 1 1 2 1 1 FIB4 Index FIB4 Index cut off 2.67 2.67 12,059 FIB4 IndexFIB4 Index 2.67 / FIB4 Index AST ALT FIB4 Index 2.67 161 1.3% FIB4 Index 5 FIB4 Index 1.1 5 1.6 FIB4

More information

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic. Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients

Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic. Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2012;10:1162 1168 Noninvasive Assessment of Nonalcoholic Fatty Liver Disease in Obese or Overweight Patients SVEN M. A. FRANCQUE,* AN VERRIJKEN, ILSE MERTENS, GUY

More information

Nash with cirrhosis icd 10

Nash with cirrhosis icd 10 Free, official coding info for 2018 ICD-10-CM K75.81 - includes detailed crosswalks, DRG grouping and more. Free, official coding info for 2018 ICD-10-CM K74.69 - includes detailed crosswalks, DRG grouping

More information

NAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology

NAFLD & NASH. Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology NAFLD & NASH Naga Chalasani, MD, FACG Professor of Medicine and Cellular & Integrative Physiology Director, Division of GI and Hepatology Indiana University School of Medicine ACG Midwest Regional Course,

More information

Understanding your FibroScan Results

Understanding your FibroScan Results PATIENT & CAREGIVER EDUCATION Understanding your FibroScan Results This information will help you understand your FibroScan results. About FibroScan FibroScan is a specialized ultrasound machine for your

More information

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology

Non-Invasive Assessment of Liver Fibrosis. Patricia Slev, PhD University of Utah Department of Pathology Non-Invasive Assessment of Liver Fibrosis Patricia Slev, PhD University of Utah Department of Pathology Disclosure Patricia Slev has no relevant financial relationships to disclose. 2 Chronic Liver Disease

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-

More information

Four search strategies used- COPD, bronchiectasis, restrictive lung disease, and asthma.

Four search strategies used- COPD, bronchiectasis, restrictive lung disease, and asthma. b) Web appendix: Literature Search details Sources to be searched for the guidelines; Reviews (CDSR) Database of Abstracts of Reviews of Effects (DARE) Dates searched: 1980 onwards All study types English

More information

Non-invasive diagnosis of hepatitis B virus-related cirrhosis

Non-invasive diagnosis of hepatitis B virus-related cirrhosis Online Submissions: http://www.wjgnet.com/esps/ bpgoffice@wjgnet.com doi:10.3748/wjg.v20.i2.445 World J Gastroenterol 2014 January 14; 20(2): 445-459 ISSN 1007-9327 (print) ISSN 2219-2840 (online) 2014

More information

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES

NON INVASIVE EVALUATION OF DISEASE PROGRESSION IN CHRONIC LIVER DISEASES Best of EASL -, Ethiopia 29 Sep to 01 Oct, 2016 Inaugural meeting of the Sub Saharan GI-Hepatology Working Group Incorporating Best of AGA and Best of EASL NON INVASIVE EVALUATION OF DISEASE PROGRESSION

More information

Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018

Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018 Chewing the Fat on Fatty Liver Mike Kolber MD, CCFP, MSc PEIP 2018 Faculty/Presenter Disclosure Faculty: Michael Kolber Relationships with financial sponsors: Grants/Research Support: Alberta College of

More information

Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease

Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease ORIGINAL ARTICLE Background of the FIB-4 Index in Japanese Non-Alcoholic Fatty Liver Disease Takashi Wada and Mikio Zeniya Abstract Objective We investigated the distribution and characteristics of the

More information

Liver 102: Injury and Healing

Liver 102: Injury and Healing Liver 102: Injury and Healing Dawn Pease, MSN, RN, ANP-BC Brackenridge Specialty Clinics University Medical Center Brackenridge Austin, TX Seton Healthcare Family Liver 102 Outline Biochemical patterns

More information

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019

LFTs: an update A MacGilchrist PLIG meeting 31st January 2019 LFTs: an update A MacGilchrist PLIG meeting 31 st January 2019 LFTs: what are we trying to achieve? (1) The case against investigation abnormal LFTs in up to 21% of the population only 1-2% develop significant

More information

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and

Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietary supplementation in treating non-alcoholic fatty liver disease Dr. Ahmad Saedi Associate Professor School of Nutritional Sciences and Dietetics Tehran University of Medical Sciences Honorary Academic

More information

Non-Alcoholic Fatty Liver Disease

Non-Alcoholic Fatty Liver Disease Non-Alcoholic Fatty Liver Disease Varun Saxena, MD MAS Gastroenterology and Hepatology Kaiser Permanente South San Francisco Assistant Clinical Professor University of California San Francisco January

More information

A study of effect of alcohol on liver function tests (LFT) in Garhwal hills, India

A study of effect of alcohol on liver function tests (LFT) in Garhwal hills, India International Journal of Research in Medical Sciences Gogoi JB et al. Int J Res Med Sci. 2018 Jan;6(1):94-98 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20175536

More information

HEP DART 2017, Kona, Hawaii

HEP DART 2017, Kona, Hawaii HEP DART 2017, Kona, Hawaii Rong Yu 1, Ke Xu 1, Jing Li 1, Tong Sun 1, Shengjiang Zhang 2, Jinhua Shao 2, Jin Sun 2, Qiong He 3, Jianwen Luo 3, Cheng Wang 4, Yudong Wang 4, Jing Chen 4, Vanessa Wu 4, George

More information

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor

*APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor APPENDIX 1 LIST OF COINVESTIGATORS *APHP: Hôpital Beaujon Professor P Bedossa, Dr F Degos, Professor P Marcellin, Professor M Vidaud; Hôpital Cochin-Necker: Professor S Pol, Professor Ph Sogni, Professor

More information

UNIVERSA MEDICINA. Forns index as a useful noninvasive predictor of esophageal varices in liver cirrhosis

UNIVERSA MEDICINA. Forns index as a useful noninvasive predictor of esophageal varices in liver cirrhosis UNIVERSA MEDICINA September-December, 2016 Vol.35 - No.3 Forns index as a useful noninvasive predictor of esophageal varices in liver cirrhosis Rizqi Arini Siregar*, Leonardo B. Dairi*, and Gontar Alamsyah

More information

ULTRASOUND IN CHRONIC LIVER DISEASE

ULTRASOUND IN CHRONIC LIVER DISEASE ULTRASOUND IN CHRONIC LIVER DISEASE Prof. Ioan Sporea, MD, PhD Head of Department of Gastroenterology and Hepatology University of Medicine and Pharmacy, Timişoara, Romania WFUMB Center of Education (COE),

More information

NAFLD AND TYPE 2 DIABETES

NAFLD AND TYPE 2 DIABETES NAFLD AND TYPE 2 DIABETES Sonia Caprio, MD STOPNASH Symposium on the Origin and Pathways of Nonalcoholic Steatohepatitis Washington 7, 215 Global Projection of Diabetes Hossain P et al. N Engl J Med 27;356:213

More information

Evaluating Obese Persons With Abnormal Liver Chemistries

Evaluating Obese Persons With Abnormal Liver Chemistries Mary E. Rinella, MD, FAASLD Evaluating Obese Persons With Abnormal Liver Chemistries Postgraduate Course: Challenges in Management of Common Liver Diseases 275 1 25 year old obese Hispanic man with obesity,

More information

Appendix 1. Search strategies for individual databases

Appendix 1. Search strategies for individual databases Appendix 1. Search strategies for individual databases OVID Database: Ovid MEDLINE(R) Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and Ovid MEDLINE(R)

More information

Investigating and Referring Incidental Findings of Abnormal Liver Tests

Investigating and Referring Incidental Findings of Abnormal Liver Tests Investigating and Referring Incidental Findings of Abnormal Liver Tests Note on Referral Guidelines: these revised guidelines are presented as a tool to aid appropriate referral and management of common

More information

Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar

Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore

More information

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients

Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Evaluation of liver and spleen stiffness using a ultrasound guided method: Accuracy of ARFI(R) measurements in liver disease patients Poster No.: C-3242 Congress: ECR 2010 Type: Topic: Authors: Keywords:

More information

Pretreatment Evaluation

Pretreatment Evaluation Pretreatment Evaluation Disclosures Research supported by Gilead Sciences Inc.: Site investigator for HIV/HCV SWITCH Registry Study Key personnel for FOCUS HCV Screening Program through Vanderbilt University

More information

Multianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease.

Multianalyte assays with algorithmic analyses are considered investigational for the diagnosis or monitoring of patients with chronic liver disease. 2.04.41 Multianalyte Assays with Algorithmic Analysis for the Evaluation and Monitoring of Patients with Chronic Liver Disease Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date September

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH

M30 Apoptosense ELISA. A biomarker assay for detection and screening of NASH M30 Apoptosense ELISA A biomarker assay for detection and screening of NASH NASH A Global Disease In the Western countries, Non-Alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease, strongly

More information

ORIGINAL ARTICLE. Both these authors contributed equally to this study. Liver International ISSN

ORIGINAL ARTICLE. Both these authors contributed equally to this study. Liver International ISSN Liver International ISSN 1478-3223 ORIGINAL ARTICLE The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients

More information

IEHP UM Subcommittee Approved Authorization Guidelines Liver Biopsy in Conjunction with Bariatric Surgery

IEHP UM Subcommittee Approved Authorization Guidelines Liver Biopsy in Conjunction with Bariatric Surgery Policy: IEHP does not cover routine liver biopsy in conjunction with bariatric surgery due to insufficient evidence that such practice alters the clinical management of non-alcoholic fatty liver disease

More information

National Horizon Scanning Centre. Transient elastography (FibroScan) for evaluating liver fibrosis. April 2008

National Horizon Scanning Centre. Transient elastography (FibroScan) for evaluating liver fibrosis. April 2008 Transient elastography (FibroScan) for evaluating liver fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not

More information

La Steatosi epatica nel paziente con infezione da HIV

La Steatosi epatica nel paziente con infezione da HIV La Steatosi epatica nel paziente con infezione da HIV Dott. Nicola Squillace Clinica delle Malattie infettive ASST-Monza, Ospedale San Gerardo-Università di Milano-Bicocca Introduction/Background Definition

More information

Review Article Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

Review Article Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease International Journal of Endocrinology Volume 2015, Article ID 343828, 9 pages http://dx.doi.org/10.1155/2015/343828 Review Article Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty

More information

Diabetes Liver Screen

Diabetes Liver Screen YOUR LIVER AND YOUR HEALTH Diabetes Liver Screen Non-Alcoholic Fatty Liver Disease (NAFLD) PROF. SUZANNE NORRIS www.liverwellness.ie The spectrum of non-alcoholic fatty liver disease Diabetes Liver Screen

More information